％0刊期文章％A王，KAY％A针刺，MICHEL％A HAY，Alastair D.％A TONNER，Sharon％A Galal，USHMA％A Grabey，Jenna％A Carver，Tricia％APerera，Rafael％a Yu，Ly-mee％a Mollison，吉尔％一点，Paul％的农民，Andrew％a管家，Christopher C.％A Harnden，Anthony％T早期使用抗生素在患有流感的危险儿童的抗生素-like疾病（Archie）：双盲随机安慰剂控制试验％D 2021％R 10.1183 / 13993003.02819-2020％J欧洲呼吸期轴颈％p 2002819％v 58％n 4％x简介英国政府库存CO-AMOXICLAV在流感淫亵物中治疗细菌并发症。这种务实的试验研究了早期共同氨杂酸是否使用临床劣化导致的转交促进，这些儿童在主要或行走护理中的流感样疾病（ILI）中的临床恶化。在6个月至12年龄的“危险”中的“危险”儿童中的“危险”。在ILI发作后5天内呈现，每天两次随机分配给口服CO-AMOXICLAV 400/57或安慰剂5天（根据年龄±重量给药）。“危险”群体包括呼吸道，心脏和神经病症的儿童。随机化由区域分层，并使用非确定性最小化算法来平衡年龄和当前季节性流感疫苗接种状态。我们的目标样本规模为650名儿童，使我们能够检测到临床劣化从40％〜26％的临床劣化进行评级的减少，其中90％的功率和5％双尾α误差（包括25个津贴随访的百分比和1.041的通胀因数）。参与者，护理人员和调查人员被蒙蔽治疗分配。 Intention-to-treat analysis included all randomised participants with primary outcome data on reconsultation due to clinical deterioration within 28 days. Safety analysis included all randomised participants. Trial registration: ISRCTN 70714783. EudraCT 2013-002822-21.Results We recruited 271 children between February 11, 2015 and April 20, 2018. Primary outcome data were available for 265 children. Only 61 out of 265 children (23.0%) reconsulted due to clinical deterioration. No evidence of a treatment effect was observed for reconsultation due to clinical deterioration (33 out of 133 for co-amoxiclav (24.8%) and 28 out of 132 (21.2%) for placebo; adjusted risk ratio (RR) 1.16, 95% confidence interval (CI) 0.75–1.80). There was also no evidence of a difference between groups in the proportion of children for whom one or more adverse events (AEs) were reported (32 out of 136 (23.5%) for co-amoxiclav and 22 out of 135 (16.3%) for placebo; adjusted RR 1.45, 95% CI 0.90–2.34). In total, 66 AEs were reported (co-amoxiclav, n=37; placebo, n=29). Nine serious AEs were reported per group, although none were considered related to study medication.Conclusion Our trial did not find evidence that treatment with co-amoxiclav reduces risk of reconsultation due to clinical deterioration in “at risk” children who present early with ILI during influenza season. Our findings therefore do not support early co-amoxiclav use in children with seasonal ILI.This trial did not find evidence that early co-amoxiclav use reduces reconsultation due to clinical deterioration in “at risk” children who present with influenza-like illness during influenza season https://bit.ly/3stZwnn %U //www.qdcxjkg.com/content/erj/58/4/2002819.full.pdf